Browsing by Subject "Vaccine immunogenicity"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Open Access
    The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity
    (Frontiers Media, 2021-11-18) Fresno, Carlos del; García Arriaza, Juan; Martínez Cano, Sarai; Heras Murillo, Ignacio; Jarit Cabanillas, Aitor; Amores Iniesta, Joaquín; Brandy, Paola; Dunphy, Gillian; Suay Corredera, Carmen; Pricolo, María Rosaria; Vicente, Natalia; López Perrote, Andrés; Cabezudo, Sofía; González Corpas, Ana; Llorca, Oscar; Alegre Cebollada, Jorge; Garaigorfa, Urtzi; Gastaminza, Pablo; Esteban, Mariano; Sancho, David; Sanidad Animal
    COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.